Settled
US SPR level for the week ending October 2, 2026
Starts:Sep 30, 2026, 6:00 PMEnds:Oct 7, 2026, 2:29 PM
AZRGMIKSHLMTNVGPLYPMU
Total volume
$36.8K
Largest spread
—
Outcomes
12
Platforms
1
Markets
1
Markets
Every market on this event, moneyline first. Select one to compare it across platforms in the side panel.
| Outcome | Best | Volume | Azuro | Gemini | Kalshi | Limitless | Novig | Polymarket | Polymarket US |
|---|---|---|---|---|---|---|---|---|---|
Above 278M Winner | 99.0%Kalshi | $1.3K | — | — | — | — | — | — | |
Above 279M Winner | 99.0%Kalshi | $3.2K | — | — | — | — | — | — | |
Above 280M Winner | 99.0%Kalshi | $2.4K | — | — | — | — | — | — | |
Above 281M Winner | 99.0%Kalshi | $2.6K | — | — | — | — | — | — | |
Above 282M Winner | 99.0%Kalshi | $1.8K | — | — | — | — | — | — | |
Above 283M | 24.0%Kalshi | $1.4K | — | — | — | — | — | — | |
Above 284M | 2.0%Kalshi | $747 | — | — | — | — | — | — | |
Above 285M | 1.0%Kalshi | $7.8K | — | — | — | — | — | — | |
Above 286M | 1.0%Kalshi | $8.6K | — | — | — | — | — | — | |
Above 287M | 1.0%Kalshi | $2.6K | — | — | — | — | — | — | |
Above 288M | 1.0%Kalshi | $2.1K | — | — | — | — | — | — | |
Above 289M | 1.0%Kalshi | $2.1K | — | — | — | — | — | — |
Above 278MWinner
99.0%Best · Kalshi$1.3K
Above 279MWinner
99.0%Best · Kalshi$3.2K
Above 280MWinner
99.0%Best · Kalshi$2.4K
Above 281MWinner
99.0%Best · Kalshi$2.6K
Above 282MWinner
99.0%Best · Kalshi$1.8K
Above 283M
24.0%Best · Kalshi$1.4K
Above 284M
2.0%Best · Kalshi$747
Above 285M
1.0%Best · Kalshi$7.8K
Above 286M
1.0%Best · Kalshi$8.6K
Above 287M
1.0%Best · Kalshi$2.6K
Above 288M
1.0%Best · Kalshi$2.1K
Above 289M
1.0%Best · Kalshi$2.1K
Description from Kalshi. A cross-platform summary is generated once this event is matched across platforms.
This market resolves based on the Weekly Petroleum Status Report for the relevant week, released on Wednesday morning following the stated week-ending date, using the value on Table 1 of the U.S. Petroleum Balance Sheet, row “Strategic Petroleum Reserve (SPR)”, under the Current Week column.
Discussion (0)
Log in to join the discussion.
No comments yet — start the discussion.